Vir Biotechnology Inc (VIR)

May 05, 2026

Vir Biotechnology Q1 2026 earnings preview - MSN

May 05, 2026

May 05, 2026

Insider Sell: Vicki Sato Sells 22,000 Shares of Vir Biotechnology Inc (VIR) - GuruFocus

May 05, 2026

May 05, 2026

Vir Biotechnology schedules CEO fireside chat at major healthcare event - Traders Union

May 05, 2026

May 05, 2026

Vir Biotechnology to Participate in Bank of America Securities 2026 Healthcare Conference - marketscreener.com

May 05, 2026

May 04, 2026

Vir Biotechnology (NASDAQ:VIR) Director Vicki Sato Sells 22,000 Shares - MarketBeat

May 04, 2026

May 04, 2026

Vir Biotechnology director Vicki Sato sells $221,025 in stock By Investing.com - Investing.com South Africa

May 04, 2026

May 04, 2026

Vir Biotechnology director Vicki Sato sells $221,025 in stock - Investing.com

May 04, 2026

May 04, 2026

Vir Biotechnology (VIR) director sells 22,000 shares under 10b5-1 plan - Stock Titan

May 04, 2026

May 03, 2026

Vir Biotechnology, Inc. (NASDAQ:VIR) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat

May 03, 2026

Apr 30, 2026

Vir Biotechnology (VIR) CEO shifts 467,064 shares into family trust - Stock Titan

Apr 30, 2026

Apr 30, 2026

Vir Biotechnology | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo

Apr 30, 2026

Apr 30, 2026

Insider resale notice: Company (NASDAQ: VIR) plans common stock sales - Stock Titan

Apr 30, 2026

Apr 30, 2026

Vir Biotechnology prices $150M stock offering - MSN

Apr 30, 2026

Apr 29, 2026

[SCHEDULE 13G] Vir Biotechnology, Inc. Passive Investment Disclosure (>5%) - Stock Titan

Apr 29, 2026

Apr 29, 2026

Why Vir Biotechnology (VIR) Is Down 5.1% After Astellas Oncology Deal And Brii Arbitration - Yahoo Finance

Apr 29, 2026

Apr 29, 2026

Vir Biotechnology (VIR) Expected to Announce Quarterly Earnings on Wednesday - MarketBeat

Apr 29, 2026

Apr 28, 2026

Needham Maintains Vir Biotechnology(VIR.US) With Buy Rating, Maintains Target Price $18 - Moomoo

Apr 28, 2026

Apr 28, 2026

Barclays Maintains Vir Biotechnology(VIR.US) With Buy Rating, Maintains Target Price $30 - Moomoo

Apr 28, 2026

Apr 27, 2026

Brii Bio reports durable HCB control in Phase II analysis - The Pharma Letter

Apr 27, 2026

Apr 26, 2026

Vir Biotechnology launches $200M public stock offering - MSN

Apr 26, 2026

Apr 26, 2026

Certain Stock options of Vir Biotechnology, Inc. are subject to a Lock-Up Agreement Ending on 27-APR-2026. - marketscreener.com

Apr 26, 2026

Apr 26, 2026

Is VIR a Good Stock to Buy? - HarianBasis.co

Apr 26, 2026

Apr 26, 2026

Is Vir Biotechnology, Inc. (VIR) A Good Stock To Buy Now? - Insider Monkey

Apr 26, 2026

Apr 26, 2026

Certain Common Stock of Vir Biotechnology, Inc. are subject to a Lock-Up Agreement Ending on 27-APR-2026. - marketscreener.com

Apr 26, 2026

Apr 24, 2026

Press Release: Vir Biotechnology to Host Conference Call for First Quarter 2026 Financial Results - 富途牛牛

Apr 24, 2026

Apr 24, 2026

Vir Biotechnology to Host Conference Call for First Quarter 2026 Financial Results - BioSpace

Apr 24, 2026

Apr 23, 2026

Vir Biotechnology to release Q1 2026 earnings on May 6 ahead of investor call - Traders Union

Apr 23, 2026

Apr 23, 2026

Vir Biotechnology Marks Key Hepatitis B Milestone With Phase 2 Combo Study Update - TipRanks

Apr 23, 2026

Apr 22, 2026

Vir Biotechnology Expands Oncology Pipeline via Astellas Partnership - HarianBasis.co

Apr 22, 2026

Apr 22, 2026

Vir Biotechnology (VIR) Posts 80.98% Year-To-Date Growth - Insider Monkey

Apr 22, 2026

Apr 21, 2026

VIR Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan

Apr 21, 2026

Apr 21, 2026

Vir Biotechnology (VIR) Is Up 19.1% After Astellas Cancer Pact Closes With $315M Inflows - simplywall.st

Apr 21, 2026

Apr 21, 2026

Vir Biotechnology Doses First Patient in Prostate Cancer Clinical Trial - HarianBasis.co

Apr 21, 2026

Apr 20, 2026

Vir Biotechnology stock hits 52-week high at $10.94 By Investing.com - Investing.com Australia

Apr 20, 2026

Apr 20, 2026

Vir Biotechnology (NASDAQ:VIR) Sets New 1-Year HighHere's Why - MarketBeat

Apr 20, 2026

Apr 20, 2026

Can Vir Biotechnology (VIR)’s Masked T-Cell Technology Crack the Hardest-to-Treat Prostate Cancer? - insidermonkey.com

Apr 20, 2026

Apr 20, 2026

Vir Biotechnology stock hits 52-week high at $10.94 - Investing.com

Apr 20, 2026

Apr 19, 2026

Is Vir Biotechnology (VIR) One of the Best Low Priced Biotech Stocks to Invest In? - Insider Monkey

Apr 19, 2026

Apr 18, 2026

8 Best Low Priced Biotech Stocks to Invest In - Insider Monkey

Apr 18, 2026

Apr 17, 2026

Vir Biotechnology, Inc. (VIR) Stock Analysis: Exploring a Potential 101% Upside in the Biotech Sector - DirectorsTalk Interviews

Apr 17, 2026

Apr 16, 2026

Vir Biotechnology, Inc. ($VIR) CEO 2025 Pay Revealed - Quiver Quantitative

Apr 16, 2026

Apr 16, 2026

[ARS] Vir Biotechnology, Inc. SEC Filing - Stock Titan

Apr 16, 2026

Apr 16, 2026

Sanofi (SNY) Benefits from Vir Biotechnology's Collaboration wit - GuruFocus

Apr 16, 2026

Apr 16, 2026

Vir Biotechnology closes $240M Astellas deal for cancer drug By Investing.com - Investing.com Australia

Apr 16, 2026

Apr 16, 2026

Vir Biotechnology, Inc. Receives $240 Million Upfront Payment and $75 Million Equity Investment from Astellas - marketscreener.com

Apr 16, 2026

Apr 16, 2026

Vir Biotechnology Announces Closing of Global Strategic Collaboration with Astellas for the Treatmen - PharmiWeb.com

Apr 16, 2026

Apr 16, 2026

Vir Biotechnology Completes Astellas Deal to Advance Prostate Cancer Immunotherapy - Contract Pharma

Apr 16, 2026

Apr 16, 2026

Vir Biotechnology (NASDAQ: VIR) sets 2026 meeting and pay vote - Stock Titan

Apr 16, 2026